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Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma.
Procarbazine (PCB) has been used for treating gliomas for many years and here both agents were combined in the treatment. This
phase I study was designed to evaluate the efficacy and safety of TMZ alone (course 1) and TMZ in combination with PCB in
subsequent courses in chemotherapy-naı ¨ve patients with malignant glioma. Patients with anaplastic astrocytoma (AA), glioblastoma
multiforme (GBM) and low-grade glioma were treated with TMZ 200mgm
 2 on days 1–5 on a 28-day cycle for course 1. Beginning
with course 2, cohorts of patients received TMZ at full dose with escalating doses of PCB (50/75/100/125mgm
 2 days 1–5 given 1h
prior to TMZ). A total of 28 patients were enrolled with three patients each at dose level 1 and 2, 16 patients at dose level 3 and six
patients at dose level 4 received 182þ cycles of treatment and were included in this analysis. In all, 16 patients had GBM, seven
patients had AA, five had grade 1 or 2 glioma and the median age was 47 years. The patients had received prior surgery and
radiotherapy. Responses were seen at all dose levels. Overall, there were 10 (36%) responses lasting from 2 to 17þ months.
Treatment was generally well tolerated with few grade 3 or 4 toxicities, except at dose level 4, where four patients had grade 3/4 had
thrombocytopaenia at this dose and several patients had moderate-to-severe lethargy. TMZ 200mgm
 2 and PCB 100mgm
 2 were
well tolerated on a daily 5  and four weekly cycle in patients with malignant glioma and clearly had antitumour activity.
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Prognosis with patients with glioma, and in particular, high-grade
(anaplastic astrocytoma (AA) and glioblastoma multiforme
(GBM)) tumours is poor. Studies have confirmed the beneficial
effect of postoperative cranial irradiation, but in most series,
survival beyond 2 years is 15% or less (Walker et al, 1978; Stewart,
1989; Fine et al, 1993). The most widely used combination in
treating gliomas is procarbazine, CCNU (lomustine), vincristine
(PCV). This has a limited effect on survival (Levin et al, 1980;
Sandberg-Wollheim et al, 1991). The most active agents identified
until recently were the nitrosoureas (BCNU, CCNU, methyl-CCNU
and HECNU), and have been reported to induce responses in the
range of 35–55%. However, the majority of these responses were
of short duration (Rodriguez and Levin, 1987; Georges et al, 1988;
Stewart, 1989).
Temozolomide came from a synthetic programme of a number
of imidazotetrazine derivatives, which exhibited broad-spectrum
antitumour activity against murine models (Stevens et al, 1984).
TMZ was selected for further clinical development in view of
its good experimental antitumour activity and low toxicity in
the pre-clinical screen. In addition, its antitumour activity was
also schedule-dependent (Stevens et al, 1987). In the early
clinical development of TMZ, administration of a single
dose induced myelosupression but did not have any antitumour
activity. However, when given on a daily 5  schedule repeated
every 4 weeks, activity against malignant melanomas and gliomas
was seen (Newlands et al, 1992). TMZ spontaneously ring opens at
physiological pH to produce the active intermediate MTIC, which
methylates DNA at a number of sites. The main cytotoxic lesion
induced by TMZ is probably at the O
6 position of guanine (Tisdale,
1987; Baer et al, 1993; Wedge et al, 1996). This cytotoxic lesion is
repaired by the DNA-repair protein O
6-alkylguanine DNA
alkyltransferase (AGT) that accepts the methyl group onto a
cysteine residue and is autoinactivated. TMZ, especially adminis-
tered in repeat dosing, will deplete tumour cells of AGT (D’Incalci
et al, 1991; Mitchell and Dolan, 1993).
PCB has been used as an oral agent for many years in patients
with malignant lymphomas (MOPP (mustine, vincristine, procar-
bazine, and prednisolone)) and in PCV-treated malignant gliomas.
A number of studies in the 1990s also identified that procarbazine,
a DNA-alkylating agent, depletes AGT (Schold et al, 1989; Souliotis
et al, 1990; Valvanis et al, 1994; Russell et al, 1995). This study was
designed to identify whether there is potentially an increase in the
therapeutic index by combining PCB and TMZ in treating patients
with malignant gliomas.
PATIENTS AND METHODS
Following ethics committee approval, 28 patients with malignant
gliomas were enrolled in this study and their details are shown in
Table 1. All had received prior surgery and radiotherapy, and none
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lhad received chemotherapy and all had progressive disease.
The study design was such that TMZ alone was administered
during course 1 to determine whether or not each patient’s
bone marrow was sensitive to TMZ at full dose. The second and
subsequent courses of TMZ were combined with escalating doses
of PCB (Table 2). If a patient’s bone marrow was sensitive to TMZ
at a dose of 200mgm
 2 daily 5 , this was reduced in the second
course to 150mgm
 2 daily 5 , and then subsequent courses
combined with PCB and the reduced dose of TMZ. Patients
continued on 4 weekly courses of TMZ at the same dose of PCB
until disease progression or evidence of major toxicity.
Responses were assessed clinically and radiologically before and
after each course of treatment. Patients with gliomas had to be
taking a stable dose of corticosteroid for at least 2 weeks before
study entry and the baseline CT or MRI scan. Radiological
shrinkage alone was not considered an acceptable measure of
response in brain tumours, as there is often difficulty in forming
clear margins on a CT or MRI abnormality, which includes
additional areas of necrosis, oedema, and vascularity. In some
cases, it may be possible to measure a clearcut reduction of 50% by
CT or MRI, but in most cases it is only possible to determine a
reduction in enhancement and mass effect. An objective response
(OR) was defined as one that requires improvement in the Medical
Research Council neurological status (Table 3) by one grade as well
as a clear-cut reduction in mass effect on CT or MRI assessment
with a minimum duration of 4 weeks. There should also be no
deterioration in any other neurological symptom or sign and no
development of new neurological deficits. Responses had to be
documented by two observations at least 4 weeks apart (Brock et al,
1998).
RESULTS
In general, the combination of TMZ and PCB was well tolerated.
Dose level 1 (PCB 50mgm
 2 per day given 1h prior to TMZ) from
course 2 onwards was well tolerated without any major side effects,
as was dose level 2 (PCB 75mgm
 2 daily 5). The only significant
toxicity at these two dose levels was lymphocytopenia (Table 4). At
dose level 3 (PCB 100mgm
 2 at daily 5), two patients had falls in
their white counts and four patients had thrombocytopenia all on
TMZ alone. One patient had thrombocytopenia from the
combination of TMZ and PCB. At dose level 4, toxicity was seen
and four patients had thrombocytopenia and several patients had
moderate-to-severe lethargy and malaise. The recommended dose
for future studies is dose level 3. The other toxicities that were seen
were skin rashes (two patients) and one patient had hepatitis A
infection (Table 5).
The responses by tumour grade are shown in Table 6. Responses
were seen in all types of glioma, with an overall response rate of
36%. Table 7 shows the response by PCB dose and responses were
seen at all dose levels. Table 8 shows the duration of responses to 1
September 2001, the duration of responses lasting from 2 to 17þ
months. Figure 1 shows a response in a patient receiving treatment
at dose level 3.
DISCUSSION
Using the criteria of response, we have previously published
responses in patients with high-grade gliomas (AA and GBM) to
TMZ that are well documented and approximately one in four
patients achieves an objective response with clearcut neurological
improvement and reduction in the area of enhancement on their
MRI scan (Brock et al, 1998). A further 25% have disease
stabilisation in terms of their MRI scans and some neurological
improvement when TMZ is given in the dose of 200mgm
 2 days
1–5 schedule repeated at 4 weekly intervals. In the randomised
study of TMZ against PCB, the response rate to PCB was lower, the
duration of those responses shorter, and the quality of life poorer.
However, PCB clearly had modest activity against high-grade
gliomas (Yung et al, 2000).
Table 1 Clinical structure: temozolomide and procarbazine phase I
Clinical details Numbers
Gender
Male 17
Female 11
Age
Median 47
Range 18–67
Diagnosis
Glioma
Glioma Grade 2 3
Glioma Grade 3 7
Glioma Grade 4 16
Oligodenroglioma
Grade 2 1
Oligodenroglioma–Astrocytoma
Grade 2 1
Total entered 28
Table 2 Study design: temozolomide and procarbazine phase I
Course Period
Course 1
Temozolomide 200mgm
 2day
 1 Days 1–5 q 28 days
Course 2
Dose Subsequent courses:
Level 1 Procarbazine 50mgm
 2day
 1 1h Days 1–5 q 28 days
Before temozolomide 200mgm
 2day
 1 Days 1–5
Dose Subsequent courses:
Level 2 Procarbazine 75mgm
 2day
 1 1h Days 1–5 q 28 days
Before temozolomide 200mgm
 2day
 1 Days 1–5
Dose Subsequent courses:
Level 3 Procarbazine 100mgm
 2day
 1 1h Days 1–5 q 28 days
Before temozolomide 200mgm
 2day
 1 Days 1–5
Dose Subsequent courses:
Level 4 Procarbazine 125mgm
 2day
 1 1h Days 1–5 q 28 days
Before temozolomide 200mgm
 2day
 1 Days 1–5
Table 3 Medical Research Council Neurological Status
0 No neurological deficit
1 Some neurological deficit, but function adequate for useful work
2 Neurological deficit causing moderate functional impairment (e.g. being able to move limb(s)) only with difficulty, moderate dysphasia, moderate paresis,
and some visual disturbances (e.g. visual field defect)
3 Neurological deficit causing major functional impairment for example inability to move limbs, gross speech, or visual disturbance
4 No useful function; inability to make conscious responses
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lIn this study, the combination of TMZ and PCB was generally
well tolerated at doses up to dose level 3. At this dose level, there is
little difference in terms of side effects between TMZ alone and the
combination with PCB. We had intended to extend this cohort to
30 or 40 patients to identify whether or not the combination was
superior to TMZ on its own. However, the supply of PCB was
interrupted and the study had to be suspended when a total of 16
patients had been entered at dose level 3. Clearly, these results on a
small number of patients are preliminary. The clinical impression
is that the combination probably is a bit more active than TMZ on
its own, and it may be that some of the patients who would
otherwise have been classified as having stable disease would have
moved into the responding group, suggesting a greater antitumour
activity when the two agents are given together.
CONCLUSION
TMZ and PCB, when combined at the recommended dose levels,
are a reasonably effective and well-tolerated combination in
treating patients with relapsed gliomas and tumour activity is
seen in low-grade gliomas, AA, and GBM.
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